Navigation Links
New Genedata Selector Release Enhances Automation Support for Biosafety Applications

Genedata, the leading provider of enterprise software for biopharmaceutical R&D, today announced a new release of its first-in-class Genedata Selector® software platform that enables the automation of complex next-generation sequencing (NGS) based workflows. The new release Genedata Selector 7.0 provides important new functionalities that automate the detection of adventitious agents and the assessment of cell line stability. Coupled with scientific domain expertise, Genedata is well-positioned to address the growing demands of the biopharmaceutical industry related to the digitalization of NGS-based workflows from early cell line engineering to late quality and biosafety testing.

Genedata Selector enables customers to perform NGS-based biosafety in-house rather than outsourcing to external providers and thus streamlines the entire biosafety testing process. With Genedata Selector, results can be generated in hours rather than weeks. More and more leading biopharmaceutical companies are now adopting Genedata Selector for biosafety assessment and quality control due to its efficient data management, unique data integration, and scalable data analysis capabilities. The adoption of the software provides a higher throughput and ultimately results in reduced costs per tested sample, while enabling biopharmaceutical companies to protect their valuable IP.

Beyond software, Genedata provides consulting services in support of developing NGS-based assays for biosafety testing.

Release 7.0 of Genedata Selector strengthens:

  • Cell Line Heterogeneity and Stability Analysis with a new functionality based on single-cell RNA sequencing (ScRNAscRNA-Seq), which can be combined with variant analysis capabilities to assess cell line stability.
  • Process Transparency and Control, by providing new comprehensive overviews of activities related to ongoing processes, and new playbooks (step-by-step guided interfaces), which enable greater insight on data analysis, sample tracking, and reporting. In particular, these new features support internal release processes, as well as automation and compliance requirements.
  • Data Security, enabling the tracking of samples and full control of user access to data during the whole analytical process, which is particularly important for IP protection and regulatory compliance.
  • Team Onboarding and Collaboration, through enhanced user interfaces that enable efficient collaboration between different users and sharing of data across functional units. This also accelerates the onboarding of new team members.

In addition to quality monitoring, biopharmaceutical companies are also leveraging Genedata Selector to streamline all their NGS-related workflows in cell line development and bioprocess optimization. This allows companies to track all their NGS and related data throughout the entire development process in a secure, transparent, in-house system.

“With Genedata Selector, our focus is on eliminating major bottlenecks in biopharmaceutical development by automating complex NGS-based workflows,” said Dr Othmar Pfannes, CEO of Genedata. “With this latest release, we have made a major step forward in streamlining a key workflow in assessing the biosafety of innovative biotherapeutics. With Genedata Selector, we remain committed to continuously improving other NGS-based workflows to support the biopharmaceutical industry in their goal to become more efficient in their R&D processes."

About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI in their R&D, spanning early discovery all the way to the clinic. Founded in 1997, Genedata is headquartered in Switzerland with additional offices in Germany, Japan, Singapore, the UK, and the US.
LinkedIn | Twitter | YouTube

Helena Bonin
Public Relations

The statements in this press release that relate to future plans, events, or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at

Source: PRWeb
Copyright©2021 Vocus, Inc.
All rights reserved

Related biology technology :

1. Genedata Enables Research to Improve Personalized Treatment of Breast and Ovarian Cancer
2. Genedata Screener 11 with Compound Combination Screening and Collaboration in the Cloud Announced at Bio-IT World 2013
3. Genedata Biologics for Biopharma R&D at Ninth Annual PEGS
4. AB Enzymes Chooses Genedata Selector for Production Strain Development and Optimization
5. New Genedata Expressionist for Mass Spectrometry Showcases at 2013 ASMS
6. Genedata at ESACT Announces Expansion Into Biopharma Process Development
7. Genedata Screener Extends Support for High-Throughput Thermofluor Assays
8. Genedata Screener Global User Group Meetings Will Examine Advancements in Plate-based Screening
9. Evonik and Genedata Broaden Their Collaboration with the Genedata Selector Biotechnology Data Management Platform
10. Sanofi Adopts Genedata Biologics for Integrated Biopharma R&D Process Support
11. Biogas Consortium Using Genedata Selector for Metagenomics-based Process Optimization
Post Your Comments:
(Date:3/27/2021)... ... March 24, 2021 , ... ... Life Sciences and Healthcare firms of all sizes, adds depth to its team ... specialist. Pardillo, who earned his doctorate in computational chemistry from Florida International University ...
(Date:3/27/2021)... ... March 24, 2021 , ... ABI Wellness, ... and reporting approach designed under CEO Mark Watson, today announced a webinar dedicated ... featuring guest speakers Dr. Cameron Clark, Neuropsychologist and Founder of Sharp Thinking, and ...
(Date:3/27/2021)... ... ... The Xtalks editorial team is pleased to announce the launch of the ... joined by editorial team members Ayesha Rashid, Sydney Perelmutter and Mira Nabulsi to discuss ... including insights from industry experts. , The Xtalks Life Science podcast will feature ...
(Date:3/23/2021)... Conn. (PRWEB) , ... March 23, 2021 , ... ... develops solutions for characterizing microbiome populations down to the strain level, recently unveiled ... applications. , Not all microbes are created equal: some are easy to ...
Breaking Biology Technology:
(Date:3/27/2021)... ... March 25, 2021 , ... Phlexglobal announced ... Planet Group, has selected Phlexglobal and its innovative regulatory SaaS software, PhlexSubmission, as ... a comprehensive review of five regulatory software companies, with the review team including ...
(Date:3/27/2021)... ... 25, 2021 , ... The 2021 Virtual Conference on Clinical Trial Supply-Europe ... More and more, clinical trial supply conferences are featuring speakers and forums that ... Asymmetrex’s founder and CEO, James L. Sherley, M.D., Ph.D., presented a talk ...
(Date:3/23/2021)... ... March 23, 2021 , ... G-CON Manufacturing (G-CON), the ... by Matica Biotechnology (Matica Bio), a contract development and manufacturing organization (CDMO) specializing ... the cleanroom build out for its new GMP production facility in College Station, ...
Breaking Biology News(10 mins):